glp 1 agonist contraindications Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus glp 1 receptor agonists contraindications

Higher GLP-1 RA doses and, especially, the duration of treatment influenced the risk [61]

Cardiovascular mortality was reported in 9 of the 11 studies

Orforglipron significantly reduced HbA1c to 2.1% in a phase II clinical trial assessing its use in T2DM, while dulaglutide achieved 1.1% and a placebo achieved 0.43% [106]

In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.

recently found in a meta-analysis of predefined cardiovascular event risks for all randomized controlled trials in the SURPASS program, compared to the control group, tirzepatide had a lower risk of MACE-4 (cardiovascular death, myocardial infarction, stroke, and unstable angina) [21]